Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Berisha, B; Hoflechner, L; Wedrich, A.
Anterior chamber migration of a dexamethasone implant: a case report
SPEKTRUM AUGENHEILKD. 2021;
Doi: 10.1007/s00717-020-00481-3
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Berisha Bujar
- Co-Autor*innen der Med Uni Graz
- Höflechner Lukas
- Wedrich Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background Ozurdex (R) (Allergan Pharmaceuticals Ireland, Westport, Co. Mayo, Ireland) is a 700 mu g dexamethasone intravitreal implant, approved for the treatment of macular edema due to retinal vein occlusion, non-infectious posterior uveitis and diabetic maculopathy. Increased intraocular pressure and lens opacification are known to be common complications. Less frequently, an anterior chamber dislocation of Ozurdex (R) has also been described. According to the literature, most transplant dislocations into the anterior chamber require surgical removal. This article reports the successful repositioning of an Ozurdex (R) implant by dilating the pupil with medicinal mydriasis. Case presentation A 79-year-old woman developed persistent cystoid macular edema in the left eye after secondary intraocular lens implantation, which had been treated since March 2016 with intravitreal Ozurdex (R). The patient underwent a planned examination 4 weeks after the last Ozurdex (R) implantation. Examination of the anterior chamber revealed an Ozurdex (R) rod located in the anterior chamber between the iris and the optic of the anterior chamber lens. A medicinal mydriasis of the pupil was performed to mobilize the dislocated Ozurdex (R). After 30 min the slit lamp examination showed that the dexamethasone implant was no longer visible in the anterior chamber. The subsequent funduscopy confirmed that the Ozurdex (R) implant was relocated in the vitreous cavity. Conclusion The removal of the Ozurdex (R) implant from the anterior chamber is necessary to avoid corneal endothelial decompensation; however, prior to surgical intervention, it is recommended to attempt repositioning of the Ozurdex (R) implant by dilating the pupil by medicinal mydriasis.
- Find related publications in this database (Keywords)
- Dislocation
- Reposition
- Ozurdex
- Vitreous body
- Mydriasis